To study the role of IRF4 in pancreatic cancer we made use of a transplantable, orthotopic tumor model using the tumor cell line T110299, which originate from a genetically engineered, spontaneous mouse model with PDAC-characteristic driver mutations (KrasG12D Tp53R172H). Here, IRF4 is linked to pancreatic neoplasm.